RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis (“MD&A”) and related management certifications (the “Interim Disclosure Documents”) by July 30, 2020.
- 0 Comments
- FY2020